Hydroxychloroquine Arm of RECOVERY Trial Halted

Jun 8, 2020 | COVID-19

On June 5, 2020, the chief investigators of the RECOVERY Trial announced that enrollment of participants to the hydroxychloroquine arm of the trial has been halted, based on analysis of data demonstrating no beneficial effect of hydroxychloroquine in patients hospitalized with COVID-19.

The RECOVERY trial is a randomized controlled trial evaluating multiple treatments for COVID-19-related severe acute respiratory syndrome (SARS) in hospitalized patients. The trial is evaluating the following therapies:

  • Lopinavir-Ritonavir

  • Corticosteroid

  • Hydroxychloroquine

  • Azithromycin

  • Convalescent plasma

  • Tocilizumab

Investigators issued a statement on preliminary results of the hydroxychloroquine arm of the trial, reporting no significant difference in the primary endpoint of 28-day mortality (25.7% hydroxychloroquine vs. 23.5% usual care; hazard ratio 1.11 [95% confidence interval 0.98-1.26]; P=0.10). There was also no evidence of beneficial effects on hospital stay duration or other outcomes. These results are not yet published.

Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5 June 2020. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. Available at: click here. Accessed June 6, 2020.

Share This